(Q33382912)

English

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

Alba A. Brandes

object named as

Alba A Brandes

1

0 references

Roberto Labianca

object named as

R Labianca

9

0 references

Armando Santoro

object named as

A Santoro

5

0 references

author name string

A Tosoni

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E Franceschi

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

V Blatt

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Faedi

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

P Amistà

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Gardiman

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C Bianchini

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Ermani

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Reni

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

24 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

769-775

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s00280-009-0926-8

0 references

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

New strategy developments in brain tumor therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Logistic regression model of fotemustine toxicity combining independent phase II studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

Positive phase II study in the treatment of advanced malignant melanoma with fotemustine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

14 July 2018

How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-009-0926-8

21 January 2018

Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-009-0926-8

21 January 2018

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

31 October 2018

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

31 October 2018

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

31 October 2018

Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

31 October 2018

Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

31 October 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2717374

31 October 2018

Predicting lung cancer by detecting aberrant promoter methylation in sputum

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of the novel nitrosourea S10036 in rodent tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19169684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-009-0926-8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33382912&oldid=1606624821"